Management
Chairman, Ying-Chu Shih, Ph.D.
Dr. Shih is specialized in the pharmaceutical research and early drug development in immunology, for diseases such as asthma, rheumatoid arthritis, liver diseases, and related areas. She worked as a research fellow, project leader, and project manager and as a director coordinating a team of 25 staff at ITRI, a leading biomedical R&D institution in Taiwan. Her experience also includes regulatory affairs and clinical trials. She is an author or co-author of five peer-reviewed publications and a co-inventor on 20 patents/patent applications. Dr. Shih has been involved with new drug R&D for more than 10 years and has led intensive R&D in botanical medicine in addition to immunological drug research. She has served as industrial drug product development consultant for New Taipei Government. She was also a biological expert member of Bureau of National Standard, Metrology & Inspection, MOEA, Taiwan.
She received a Ph.D. in Biosciences from the University of Birmingham at Birmingham, UK, and did postdoctoral work at the National Taiwan University, a MS in microbiology and Immunology, the National Taiwan University, and a BS in Life Sciences, National Tsing Hua University. She has received many intensive management trainings including a high level eMBA program “iMMOT” by ITRI. She has been a member of the General Microbiology Society.
 
General Manager,Hung-Chang Yuan
Mr. Yuan graduated from National Chiao Tung University with a Master degree in Finance. He previously worked for an IPO company as a manager in Financial and Administration department.  He has good knowledge and working experience in the Banking Act, Securities of Exchange Act of Taiwan.  
 
VP of R&D, Syaulan Yang, Ph. D. 
Dr. Yang has had more than 23 year of experience in pharmaceutical industry. His expertise includes drug development, drug design and synthesis, scale-up and process development, etc., especially in anti-inflammatory and antiviral medicines. He served in Pfizer (Searle) (US), TaiGen Biotech (Taiwan), Oriental Union Chemical (Taiwan), Zannan Pharma (Shanghai), ChemDeveloping Biotech (Shanghai) and ever involved or led two compounds into Phase I trials. While in the area of business management, Dr. Yang has had more than ten years of experience in corporate executive positions. He is familiar with business management, corporate establishment, as well as exploitation and development, for a start-up company.
Prior to his Ph.D. degree in Chemistry from Johns Hopkins University, Dr. Yang received his B.S. degree in Chemistry from the National Chung-Hsing University in Taiwan.  He did postdoctoral research followed by research associate in Northwestern University (US). He is a co-inventor of four patents and a co-author of fourteen publications in peer-reviewed journals.
 
VP of Clinical Development, Loren Miller, Ph.D.
Dr. Miller has more than 20 years of experience in clinical regulatory affairs. He has served in several executive positions at PPD Development, including Vice President, Scientific and Regulatory Affairs. Prior to joining PPD, he held many senior and management positions in clinical research and regulatory affairs at Quintiles and GlaxoWellcome. After graduating from the University of Kentucky with a Ph.D., he taught at the University of Kentucky Medical Center and VA Hospital as an Assistant Professor in Psychiatry. Dr. Miller is a co-author of more than 50 peer reviewed publications.